Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease

被引：18

作者：

Detrez, Iris ^{[1
]}

Van Stappen, Thomas ^{[1
]}

Martin Arranz, Maria D. ^{[2
]}

Papamichael, Kostas ^{[3
]}

Gils, Ann ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Lab Therapeut & Diagnost Antibodies, Dept Pharmaceut & Pharmacol Sci, O&N 2 Herestraat 49,Box 820, B-3000 Leuven, Belgium

[2] Hosp Univ La Paz, IBD Unit & Endoscopy, Dept Gastroenterol & Hepatol, Madrid, Spain

[3] Harvard Med Sch, Div Gastroenterol, Ctr Inflammatory Bowel Dis, Beth Israel Deaconess Med Ctr, Boston, MA USA

来源：

THERAPEUTIC DRUG MONITORING | 2017年 / 39卷 / 04期

关键词：

biopharmaceuticals; inflammatory bowel disease; therapeutic drug monitoring; TNF MONOCLONAL-ANTIBODIES; NECROSIS-FACTOR-ALPHA; CROHNS-DISEASE; MAINTENANCE THERAPY; DOSE INTENSIFICATION; ENDOSCOPIC OUTCOMES; CLINICAL-RESPONSE; SERUM INFLIXIMAB; PHARMACOKINETICS; ASSOCIATION;

D O I：

10.1097/FTD.0000000000000394

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Since the late 90s, biopharmaceuticals targeting tumor necrosis factor alpha have revolutionized the treatment of moderately to severely active inflammatory bowel disease. The robust efficacy witnessed in many patients stands in stark contrast with the observation of a proportion of patients who fail to respond or who lose response over time. Therapeutic drug monitoring has been proposed as a means to understand and respond to the variability in clinical response and remission. Various treatment algorithms have been proposed, but optimal use of these measurements in daily practice awaits additional prospective validation trials. This review provides an updated overview on the subject of therapeutic drug monitoring of biopharmaceuticals for the management of inflammatory bowel disease and how we could implement its concepts in a changing landscape.

引用

页码：344 / 349

页数：6

共 58 条

[1] Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis [J].

Adedokun, Omoniyi J. ;

Sandborn, William J. ;

Feagan, Brian G. ;

Rutgeerts, Paul ;

Xu, Zhenhua ;

Marano, Colleen W. ;

Johanns, Jewel ;

Zhou, Honghui ;

Davis, Hugh M. ;

Cornillie, Freddy ;

Reinisch, Walter .

GASTROENTEROLOGY, 2014, 147 (06) :1296-+

[2] Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease [J].

Afif, Waqqas ;

Loftus, Edward V., Jr. ;

Faubion, William A. ;

Kane, Sunanda V. ;

Bruining, David H. ;

Hanson, Karen A. ;

Sandborn, William J. .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (05) :1133-1139

[3] Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases [J].

Amiot, Aurelien ;

Peyrin-Biroulet, Laurent .

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2015, 8 (02) :66-82

[4] Immunogenicity and autoimmunity during anti-TNF therapy [J].

Atzeni, F. ;

Talotta, R. ;

Salaffi, F. ;

Cassinotti, A. ;

Varisco, V. ;

Battellino, M. ;

Ardizzone, S. ;

Pace, F. ;

Sarzi-Puttini, P. .

AUTOIMMUNITY REVIEWS, 2013, 12 (07) :703-708

[5] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[6] Is There a Role for Therapeutic Drug Monitoring of Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease [J].

Baert, Filip .

DIGESTIVE DISEASES, 2015, 33 :70-77

[7] Pathway-based approaches to the treatment of inflammatory bowel disease [J].

Bamias, Giorgos ;

Pizarro, Theresa T. ;

Cominelli, Fabio .

TRANSLATIONAL RESEARCH, 2016, 167 (01) :104-115

[8] Association of Ustekinumab Trough Concentrations With Clinical, Biochemical and Endoscopic Outcomes [J].

Battat, Robert ;

Kopylov, Uri ;

Bessissow, Talat ;

Bitton, Alain ;

Cohen, Albert ;

Martel, Myriam ;

Seidman, Ernest G. ;

Afif, Waqqas .

GASTROENTEROLOGY, 2016, 150 (04) :S144-S145

[9] Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal [J].

Ben-Horin, S. ;

Chowers, Y. ;

Ungar, B. ;

Kopylov, U. ;

Loebstein, R. ;

Weiss, B. ;

Eliakim, R. ;

Del Tedesco, E. ;

Paul, S. ;

Roblin, X. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (03) :356-364

[10] Targeting TNF-α for the treatment of inflammatory bowel disease [J].

Billiet, Thomas ;

Rutgeerts, Paul ;

Ferrante, Marc ;

Van Assche, Gert ;

Vermeire, Severine .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (01) :75-101

← 1 2 3 4 5 6 →